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Decrease of Morbidity and Cost of Care 
with Prophylactic Cranial Irradiation for 
Non-small Cell Lung Cancer
Purpose
While several studies analyze the incidence of brain metastases 
in patients with non-small cell lung cancer (NSCLC) treated with 
prophylactic cranial irradiation (PCI), there is little data available on 
how this treatment can affect medical cost and morbidity. Our goal 
was to analyze those issues patients encounter secondary to brain 
metastases, often in the final months of their lives, and to support the 
hypothesis of economic benefit and cost effectiveness resulting from 
the use of PCI in this population.
Method and Materials
We identified 13 consecutive patients with stage III NSCLC, who 
developed brain metastases at 5-20 months after initial primary 
tumor diagnosis, with an average of 13.5 months. All patients but four 
died, at an average of 8 months from diagnosis of brain metastases. 
We retrospectively analyzed the number of brain MRI and CT scans, 
hospital visits with length of stay, craniotomies, whole brain radiation 
and stereotactic radiation for each patient, at our hospital only, with 
accompanying estimated cost. These numbers were used to assess 
cost effectiveness and morbidities caused by the exams, surgeries, 
and hospitalizations.
Results
Eight patients had craniotomies, with 2 patients undergoing multiple 
operations. The average number of MRIs was 7, with one patient 
having 19. There was an average of 4 CT scans per patient. All patients 
had brain metastases related hospitalizations, with an average of 13.4 
days per patient. All patients received whole brain radiation therapy. 
Finally, 7 patients received stereotactic radiosurgical boost for their 
brain lesions, with two receiving multiple treatments. As a result, 
in the final 8 months of their lives, our patients spent an average 
of 13 days in the hospital, with over 10 imaging scans performed in 
this time period, and a median of one craniotomy. During those 8 
months, an estimate of minimal cost from our institution (excluding 
outside hospitalizations) on average was $57,455.
Conclusion
Brain metastases commonly occur in Stage III, NSCLC and cause 
significant morbidity and financial burden from hospital stays, 
imaging exams, and surgical interventions. Since RTOG 0214 showed 
that PCI reduced the incidence of brain metastases in these patients 
from 18 to 7.7% at 1 year, if used routinely, it could potentially reduce 
the cost in this patient population while decreasing morbidity and 
optimizing resource utilization.
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